Next-Generation Drug Discovery

Inspired by Evolution,
Accelerated by AI

Unlocking nature's vast chemical library to discover tomorrow's medicines.

Partner With Us

Decoding the World's Largest Untapped Chemical Library

PanPharm AI harnesses the power of artificial intelligence to predict natural product therapeutics from biosynthetic gene clusters. We're transforming microbial genomes into a programmable drug discovery engine, accessing the vast chemical diversity that traditional methods cannot reach.

>50%
of FDA-approved drugs from natural products
>107
novel chemical scaffolds waiting to be discovered
>1000x
faster discovery vs. traditional methods
>99%
of microbial chemistry remains unexplored

Our Platform

01

Genomic AI Engine

Predicts chemical scaffolds directly from biosynthetic gene cluster sequences using deep generative models trained on BGC-compound-target associations.

02

Molecular Generator

Proprietary algorithm to confidently predict 3D chemical structures of BGC-encoded compounds.

03

Target Docking Suite

High-throughput docking against protein targets with ML-enhanced scoring functions for binding affinity, ADMET properties, and synthetic accessibility.

04

Active Learning Loop

Integrates experimental validation results to continuously refine model predictions, creating a self-improving discovery engine.

Leadership and Advisory Team

Brad Hover
Brad Hover, PhD

Co-founder of AI/ML-enabled drug discovery company, Lodo Therapeutics (acquired by Zymergen); previously Senior Director at Odyssey Therapeutics and Zymergen. 10+ years leading natural product drug discovery, high-throughput screening, and hit-to-lead programs.

Kim Lewis
Kim Lewis, PhD

Distinguished University Professor at Northeastern University; Fellow of AAAS and the American Academy of Microbiology. Pioneer in antibiotic discovery and global leader in natural products research with 61,000+ citations.

Ayan Paul
Ayan Paul, PhD

Principal Investigator, Neural Dynamics Group, Institute for Experiential AI at Northeastern University. AI researcher with 8+ years delivering models across physics, computational biology, and drug discovery; advisor and co-founder of multiple AI startups.

Samuel Scarpino
Samuel V. Scarpino, PhD

Director of AI + Life Sciences, Institute for Experiential AI; Professor at Northeastern University; External Professor, Santa Fe Institute. 15+ years in global health security, including former Vice President at The Rockefeller Foundation.

Paul Hergenrother
Paul J. Hergenrother, PhD

Endowed Chair in Natural Products Chemistry, University of Illinois Urbana-Champaign; Fellow, National Academy of Inventors. Leader in antibiotic discovery.

Let's Build the Future
of Drug Discovery

We're seeking strategic partnerships with pharmaceutical companies, investors, and research institutions. Join us in transforming natural product discovery.